Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Inclusion Criteria:

Male patients with a diagnosis of advanced prostate cancer for whom treatment with triptorelin pamoate or leuprolide acetate is indicated;
At least 18 years of age;
Life expectancy of at least 1 year;
Capable of completing the study questionnaires without assistance.

Exclusion Criteria:

Patients for whom treatment with triptorelin pamoate or leuprolide acetate is contraindicated;
Known hypersensitivity to triptorelin, leuprolide or any other GnRH or luteinizing hormone releasing hormone (LHRH) agonists, or GnRH or LHRH;
Clinically significant systemic disease or condition that would, in the investigator's opinion, lead to undue risk following administration of either triptorelin or leuprolide;
History of alcohol/drug abuse within the past year;
History of significant medical problems that may confound the outcome of this study;
Requires concomitant medications that may affect study assessments (e.g., topical medications used for pretreatment of injection site pain);
Participated in another investigational drug study within 30 days
Judged by the investigator to be unsuitable for enrollment in this study for any reason